A top drug program at Bayer clears a high bar for CKD — opening the door to an FDA pitch
Over the past 4 years, Bayer has been steering a major trial through a pivotal program to see if their drug finerenone could slow down …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
